Targeting Prostate Cancer Using Intratumoral Cytotopically Modified Interleukin-15 Immunotherapy in a Syngeneic Murine Model.

Immunotargets Ther · 2020 · PMC7394845 · PMID 32802803

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Non-modified IL-15 at the same concentrations also increased NK cell expansion by approximately 2-fold compared with control but the result did not reach statistical significance ( Figure 1E ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.